Covidien launches next-generation stent in Europe
This article was originally published in Clinica
Executive Summary
Covidien has launched its EverFlex+ self-expanding peripheral stent in Europe. The device is a next-generation version of the EverFlex stent, originally developed by ev3, which was launched worldwide in 2006 for peripheral arterial disease and stenting of the superficial femoral artery. Covidien agreed to buy ev3 in June (www.clinica.co.uk, 2 June 2010), and the purchase was completed in July. EverFlex+, which was CE marked in October 2010, has been designed to lower the risk of fracture when elongated, thereby improving clinical outcomes. It has similar radial strength and flexibility as the older device, but greater durability, Dublin, Ireland-based Covidien claims. EverFlex+ is not currently available in the US.